Ask a doctor about a prescription for Tabagine
Pregabalin
Tabagine belongs to a group of medicines used to treat epilepsy, neuropathic pain, and generalized anxiety disorders in adults.
The medicine is used to treat long-term pain caused by nerve damage. Many different diseases, such as diabetes or shingles, can cause peripheral neuropathic pain. The pain can be described as a feeling of heat, burning, pulsation, shooting, stabbing, as sharp pain, cramps, soreness, tingling, or numbness. Peripheral and central neuropathic pain can also be associated with mood changes, sleep disturbances, fatigue, which can affect the patient's physical and social functioning and overall quality of life.
Tabagine is used in adults for certain types of epilepsy (partial seizures, which may or may not be secondarily generalized). The doctor may prescribe this medicine if the current therapy does not fully control the course of the disease. Tabagine should always be added to the currently used treatment. This medicine should not be used as the only one (in monotherapy), but always in combination with other antiepileptic drugs.
Tabagine is used in generalized anxiety disorders (English: Generalized Anxiety Disorder - GAD). The symptoms include prolonged, excessive anxiety and worry that are difficult to control. Generalized anxiety disorders can also cause restlessness, nervousness, or a feeling of being on edge, easy fatigue, difficulty concentrating or a feeling of "emptiness in the head", irritability, increased muscle tension, or sleep disturbances. The symptoms are different from the stresses and tensions of everyday life.
Before starting to take Tabagine, you should discuss it with your doctor or pharmacist.
The patient should inform their doctor about all serious diseases they have had, including liver or kidney disorders.
Some people may become dependent on pregabalin (need to continue taking the medicine). After stopping pregabalin, withdrawal symptoms may occur (see section 3 "How to take Tabagine" and "Stopping Tabagine"). If the patient is concerned that they may become dependent on pregabalin, they should talk to their doctor. If the patient notices any of the following symptoms while taking pregabalin, it may indicate dependence:
If the patient notices any of these symptoms, they should talk to their doctor to discuss the best course of treatment, including when to stop taking the medicine and how to do it safely.
The safety and efficacy of pregabalin in children and adolescents (under 18 years of age) have not been established, so pregabalin should not be used in this age group.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. Tabagine and some medicines may interact with each other (interactions). Pregabalin taken with medicines that have a sedating effect (including opioids) may enhance these effects, leading to respiratory failure, coma, and death. The degree of dizziness, somnolence, and decreased concentration may increase if pregabalin is taken with medicines containing:
Tabagine can be taken with oral contraceptives.
The capsules can be taken with or without food. The patient should not drink alcohol while taking this medicine.
Tabagine should not be taken during pregnancy or breastfeeding, unless the doctor recommends otherwise. Taking pregabalin during the first 3 months of pregnancy may cause birth defects in the unborn child. In a study analyzing data from women in Scandinavian countries who took pregabalin during the first 3 months of pregnancy, 6 out of 100 children had such birth defects. For comparison, in a study of 4 out of 100 children born to women not treated with pregabalin. There have been reports of facial abnormalities (cleft lip and palate), eye, nervous system (including brain), kidney, and genital abnormalities. Women of childbearing age must use effective contraception. If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine.
Pregabalin may cause dizziness, somnolence, and decreased concentration. The patient should not drive a car, operate complex machines, or perform potentially hazardous activities until they have determined the effects of the medicine on their ability to perform these activities.
The medicine contains less than 1 mmol (23 mg) of sodium per hard capsule, which means the medicine is considered "sodium-free". Mannitol may have a mild laxative effect.
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. If the patient has any doubts, they should consult their doctor or pharmacist. The patient should not take more of the medicine than prescribed.
The doctor will determine the dose that is most suitable for the patient. The medicine is for oral use only.
If the patient feels that the medicine is too strong or too weak, they should inform their doctor or pharmacist. Patients over 65 years of age should take the medicine according to the presented schedule, unless they have kidney disease. In patients with impaired renal function, the doctor may decide on a different dosing schedule and/or change the dose of the medicine. The capsule should be swallowed whole and washed down with water. The medicine should be taken for as long as the doctor recommends, and the treatment can only be stopped on the doctor's advice.
The patient should inform their doctor or go to the nearest hospital emergency department immediately. The patient should take the packaging of the medicine with them. After taking a higher dose than recommended, the patient may feel drowsy, confused, excited, or restless. There have also been reports of seizures.
It is important to take the medicine regularly at the same times of the day. If a dose is missed, the patient should take it as soon as possible, unless it is almost time for the next dose. In this case, the patient should continue treatment according to the prescribed schedule. The patient should not take a double dose to make up for the missed capsules.
The patient should not stop taking the medicine suddenly. If the patient wants to stop taking the medicine, they should first talk to their doctor. The doctor will inform the patient how to do this. If the treatment needs to be stopped, it should be done gradually over at least one week. The patient should be aware that after stopping short-term or long-term pregabalin treatment, side effects may occur, known as withdrawal symptoms. These symptoms include sleep disturbances, headache, nausea, anxiety, diarrhea, flu-like symptoms, seizures, nervousness, depression, thoughts of self-harm or suicide, pain, excessive sweating, and dizziness. These symptoms may be more frequent or severe if the patient has taken Tabagine for a longer period. If withdrawal symptoms occur, the patient should contact their doctor. If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Tabagine can cause side effects, although not everybody gets them.
If the patient experiences any of the following side effects, they should stop taking the medicine and contact their doctor or go to the nearest hospital immediately, as urgent medical attention may be necessary.
Pancreatitis (including symptoms: severe pain in the upper abdomen, often with nausea and vomiting) (rare, may affect up to 1 in 1,000 people)
The patient should be aware that after stopping short-term or long-term pregabalin treatment, side effects may occur, known as withdrawal symptoms (see section "Stopping Tabagine"). Some side effects, such as somnolence, may occur more frequently because patients with spinal cord injury may be taking other medicines, e.g., painkillers or muscle relaxants, which have similar side effects to Tabagine, and the severity of these effects may be greater when such medicines are taken concomitantly. Side effects reported after the medicine was placed on the market: breathing difficulties, shallow breathing. Reporting side effects If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products Al. Jerozolimskie 181C 02-222 Warsaw Tel.: +48 22 49 21 301 Fax: +48 22 49 21 309 Website: https://smz.ezdrowie.gov.pl Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. Do not use this medicine after the expiry date stated on the carton and blister packaging after "EXP". The expiry date refers to the last day of the month stated. The batch number is stated after "Lot". There are no special precautions for storing the medicine. After opening the bottle of capsules, the capsules should be used within 30 days. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of the medicine is pregabalin. Each hard capsule contains 75 mg, 150 mg, or 300 mg of pregabalin. The other ingredients are:
Hard, gelatin capsules, size 4, with a red opaque cap and a white opaque body, and black ink printing with "rbx" on the cap and "PG75" on the body, containing a white to almost white powder. The length of the capsule is about 14.0 - 14.8 mm. 75 mg capsules Hard, gelatin capsules, size 2, with a white opaque cap and a white opaque body, and black ink printing with "rbx" on the cap and "PG150" on the body, containing a white to almost white powder. The length of the capsule is about 17.0 - 18.2 mm. 150 mg capsules Hard, gelatin capsules, size 0, with a red opaque cap and a white opaque body, and black ink printing with "rbx" on the cap and "PG300" on the body, containing a white to almost white powder. The length of the capsule is about 21.0 - 21.8 mm. 300 mg capsules Blisters of OPA/Aluminum/PCV//Aluminum, PCV//Al, or HDPE bottles with PP closure, with a child-resistant closure. Tabagine is available in packs of 14 and 56 capsules. Not all pack sizes may be marketed.
Ranbaxy (Poland) Sp. z o.o. ul. Idzikowskiego 16 00-710 Warsaw
Sun Pharmaceutical Industries Europe B.V. Polarisavenue 87 2132JH Hoofddorp Netherlands Terapia S.A. Fabricii Street nr 124 400632 Cluj-Napoca, Jud. Cluj Romania Date of last revision of the leaflet:17.01.2024
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Tabagine – subject to medical assessment and local rules.